Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q87773226 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241121000318.0 | ||
| 008 | 241121nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q87773226 | ||
| 024 | ‡a 0000-0001-9327-1894 ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q87773226 | ||
| 100 | 0 | ‡a Antonio Oliver ‡c researcher ‡9 en | |
| 375 | ‡a 1 ‡2 iso5218 | ||
| 400 | 0 | ‡a Antonio Oliver ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's A Genome-Based Model to Predict the Virulence of Pseudomonas aeruginosa Isolates | ||
| 670 | ‡a Author's A Standard Numbering Scheme for Class C β-Lactamases | ||
| 670 | ‡a Author's Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants | ||
| 670 | ‡a Author's Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone | ||
| 670 | ‡a Author's Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia | ||
| 670 | ‡a Author's Clinically relevant epithelial lining fluid concentrations of meropenem with ciprofloxacin provide synergistic killing and resistance suppression of hypermutable Pseudomonas aeruginosa in a dynamic biofilm model | ||
| 670 | ‡a Author's Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308 | ||
| 670 | ‡a Author's Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections | ||
| 670 | ‡a Author's Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa ST175 in a Hollow-Fiber Infection Model. | ||
| 670 | ‡a Author's Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling | ||
| 670 | ‡a Author's Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting. | ||
| 670 | ‡a Author's Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain. | ||
| 670 | ‡a Author's In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae | ||
| 670 | ‡a Author's In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. | ||
| 670 | ‡a Author's Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model. | ||
| 670 | ‡a Author's Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens | ||
| 670 | ‡a Author's Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model. | ||
| 670 | ‡a Author's Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling | ||
| 670 | ‡a Author's Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model | ||
| 670 | ‡a Author's Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii | ||
| 670 | ‡a Author's Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms. | ||
| 909 | ‡a (orcid) 0000000193271894 ‡9 1 | ||
| 919 | ‡a interplaybetweenpeptidoglycanbiologyandvirulenceingramnegativepathogens ‡A Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens ‡9 1 | ||
| 919 | ‡a interplayamongresistanceprofileshighriskclonesandvirulenceinthecaenorhabditiseleganspseudomonasaeruginosainfectionmodel ‡A Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model. ‡9 1 | ||
| 919 | ‡a invivoemergenceofresistancetonovelcephalosporinβlactamaseinhibitorcombinationsthroughtheduplicationofaminoacidd149fromoxa2βlactamaseoxa539insequencetype235pseudomonasaeruginosa ‡A In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. ‡9 1 | ||
| 919 | ‡a invitroandinvivoactivitiesofβlactamsincombinationwiththenovelβlactamenhancerszidebactamandwck5153againstmultidrugresistantmetalloβlactamaseproducingklebsiellapneumoniae ‡A In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae ‡9 1 | ||
| 919 | ‡a genomicsandsusceptibilityprofilesofextensivelydrugresistantxdrpseudomonasaeruginosafromspain ‡A Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain. ‡9 1 | ||
| 919 | ‡a evolutionofthepseudomonasaeruginosaaminoglycosidemutationalresistomeinvitroandinthecysticfibrosissetting ‡A Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting. ‡9 1 | ||
| 919 | ‡a evaluationoftobramycinandciprofloxacinasasynergisticcombinationagainsthypermutablepseudomonasaeruginosastrainsviamechanismbasedmodelling ‡A Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling ‡9 1 | ||
| 919 | ‡a evaluationofceftolozanetazobactamincombinationwithmeropenemagainstpseudomonasaeruginosast175inahollowfiberinfectionmodel ‡A Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa ST175 in a Hollow-Fiber Infection Model. ‡9 1 | ||
| 919 | ‡a characterizationofhypermutatorpseudomonasaeruginosaisolatesfrompatientswithcysticfibrosisinaustralia ‡A Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia ‡9 1 | ||
| 919 | ‡a clinicallyrelevantepithelialliningfluidconcentrationsofmeropenemwithciprofloxacinprovidesynergistickillingandresistancesuppressionofhypermutablepseudomonasaeruginosainadynamicbiofilmmodel ‡A Clinically relevant epithelial lining fluid concentrations of meropenem with ciprofloxacin provide synergistic killing and resistance suppression of hypermutable Pseudomonas aeruginosa in a dynamic biofilm model ‡9 1 | ||
| 919 | ‡a emergenceofresistancetonovelβlactamβlactamaseinhibitorcombinationsduetohorizontallyacquiredampcfox4inpseudomonasaeruginosasequencetype308 ‡A Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308 ‡9 1 | ||
| 919 | ‡a challengingantimicrobialsusceptibilityandevolutionofresistanceoxa681duringtreatmentofalongtermnosocomialinfectioncausedbyapseudomonasaeruginosast175clone ‡A Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone ‡9 1 | ||
| 919 | ‡a activityofimipenemrelebactamagainstalargecollectionofpseudomonasaeruginosaclinicalisolatesandisogenicβlactamresistantmutants ‡A Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants ‡9 1 | ||
| 919 | ‡a standardnumberingschemeforclass100βlactamases ‡A A Standard Numbering Scheme for Class C β-Lactamases ‡9 1 | ||
| 919 | ‡a epidemiologyandtreatmentofmultidrugresistantandextensivelydrugresistantpseudomonasaeruginosainfections ‡A Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections ‡9 1 | ||
| 919 | ‡a genomebasedmodeltopredictthevirulenceofpseudomonasaeruginosaisolates ‡A A Genome-Based Model to Predict the Virulence of Pseudomonas aeruginosa Isolates ‡9 1 | ||
| 919 | ‡a useofcalgaryandmicrofluidicbiofluxsystemstotesttheactivityoffosfomycinandtobramycinaloneandincombinationagainstcysticfibrosispseudomonasaeruginosabiofilms ‡A Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms. ‡9 1 | ||
| 919 | ‡a therapeuticefficacyofln1255incombinationwithimipeneminsevereinfectioncausedbycarbapenemresistantacinetobacterbaumannii ‡A Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii ‡9 1 | ||
| 919 | ‡a synergisticmeropenemtobramycincombinationdosageregimensagainstclinicalhypermutablepseudomonasaeruginosaatsimulatedepithelialliningfluidconcentrationsinadynamicbiofilmmodel ‡A Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model ‡9 1 | ||
| 919 | ‡a regulationofampcdrivenβlactamresistanceinpseudomonasaeruginosadifferentpathwaysdifferentsignaling ‡A Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling ‡9 1 | ||
| 919 | ‡a optimizationofameropenemplustobramycincombinationdosageregimenagainsthypermutableandnonhypermutablepseudomonasaeruginosaviamechanismbasedmodelingandthehollowfiberinfectionmodel ‡A Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model. ‡9 1 | ||
| 946 | ‡a b ‡9 1 | ||
| 996 | ‡2 LC|no2005063793 | ||
| 996 | ‡2 ISNI|0000000117790027 | ||
| 996 | ‡2 RERO|A003654905 | ||
| 996 | ‡2 ISNI|0000000083569286 | ||
| 996 | ‡2 ISNI|0000000054948674 | ||
| 996 | ‡2 RERO|A003654909 | ||
| 996 | ‡2 NUKAT|n 00078525 | ||
| 996 | ‡2 BNE|XX1089561 | ||
| 996 | ‡2 CAOONL|ncf11059474 | ||
| 996 | ‡2 ISNI|0000000060885163 | ||
| 996 | ‡2 LC|n 85043136 | ||
| 996 | ‡2 ISNI|0000000116571869 | ||
| 996 | ‡2 NDL|00472510 | ||
| 996 | ‡2 CAOONL|ncf12106720 | ||
| 996 | ‡2 BNC|981058511035006706 | ||
| 996 | ‡2 ISNI|0000000384582433 | ||
| 996 | ‡2 BAV|495_235677 | ||
| 996 | ‡2 BNCHL|10000000000000000066274 | ||
| 996 | ‡2 B2Q|0000426127 | ||
| 996 | ‡2 RERO|A003655029 | ||
| 996 | ‡2 LC|nb 98089754 | ||
| 996 | ‡2 CAOONL|ncf10374906 | ||
| 996 | ‡2 BNE|XX829703 | ||
| 996 | ‡2 NLA|000035677163 | ||
| 996 | ‡2 BNE|XX893241 | ||
| 996 | ‡2 JPG|500040067 | ||
| 996 | ‡2 SUDOC|167224999 | ||
| 996 | ‡2 NTA|071397140 | ||
| 996 | ‡2 SUDOC|18820413X | ||
| 996 | ‡2 LC|no2003013159 | ||
| 996 | ‡2 LC|n 82202449 | ||
| 996 | ‡2 BNE|XX1086541 | ||
| 996 | ‡2 BNC|981058614459406706 | ||
| 996 | ‡2 ISNI|000000011871072X | ||
| 996 | ‡2 RERO|A014178826 | ||
| 996 | ‡2 PLWABN|9811508569305606 | ||
| 996 | ‡2 BNC|981058527751506706 | ||
| 996 | ‡2 LC|no2023030687 | ||
| 996 | ‡2 BIBSYS|90237384 | ||
| 996 | ‡2 BNC|981058523349106706 | ||
| 996 | ‡2 BNE|XX6021311 | ||
| 996 | ‡2 NTA|073550205 | ||
| 996 | ‡2 LC|n 81137187 | ||
| 996 | ‡2 BNC|981058527994906706 | ||
| 996 | ‡2 LIH|LNB:V-30903;=BB | ||
| 996 | ‡2 PTBNP|250725 | ||
| 996 | ‡2 LC|n 80093514 | ||
| 996 | ‡2 SUDOC|219878358 | ||
| 996 | ‡2 ISNI|000000010879814X | ||
| 996 | ‡2 BIBSYS|90541113 | ||
| 996 | ‡2 DNB|1252248679 | ||
| 996 | ‡2 ISNI|0000000059485576 | ||
| 996 | ‡2 LC|no2007132157 | ||
| 996 | ‡2 NTA|370815092 | ||
| 996 | ‡2 BIBSYS|99035865 | ||
| 996 | ‡2 J9U|987007366630305171 | ||
| 996 | ‡2 PTBNP|142815 | ||
| 996 | ‡2 SUDOC|161814476 | ||
| 996 | ‡2 SUDOC|176948694 | ||
| 996 | ‡2 NKC|xx0270195 | ||
| 996 | ‡2 BNC|981058615290606706 | ||
| 996 | ‡2 BNE|XX896364 | ||
| 996 | ‡2 BNC|981058529407606706 | ||
| 996 | ‡2 CAOONL|ncf10190473 | ||
| 996 | ‡2 BNC|981058527546206706 | ||
| 996 | ‡2 BNE|XX1223440 | ||
| 996 | ‡2 BNE|XX4802586 | ||
| 996 | ‡2 ISNI|0000000392000261 | ||
| 996 | ‡2 SUDOC|258262060 | ||
| 996 | ‡2 BNE|XX4705388 | ||
| 996 | ‡2 J9U|987007451209605171 | ||
| 996 | ‡2 DNB|1036572781 | ||
| 996 | ‡2 BIBSYS|90368166 | ||
| 996 | ‡2 NDL|01070159 | ||
| 996 | ‡2 SUDOC|221316299 | ||
| 996 | ‡2 JPG|500095527 | ||
| 996 | ‡2 BNE|XX824659 | ||
| 996 | ‡2 NTA|068838107 | ||
| 996 | ‡2 BNE|XX941361 | ||
| 996 | ‡2 J9U|987007296198405171 | ||
| 996 | ‡2 ISNI|0000000425187684 | ||
| 996 | ‡2 CAOONL|ncf10301341 | ||
| 996 | ‡2 NKC|pna20201074096 | ||
| 996 | ‡2 LC|nr 97033604 | ||
| 996 | ‡2 BNC|981058529402206706 | ||
| 996 | ‡2 BIBSYS|90875477 | ||
| 996 | ‡2 BIBSYS|90373447 | ||
| 996 | ‡2 BIBSYS|90567793 | ||
| 996 | ‡2 ISNI|0000000060764935 | ||
| 996 | ‡2 LC|no2008183578 | ||
| 996 | ‡2 ISNI|0000000070010950 | ||
| 996 | ‡2 BNE|XX6422016 | ||
| 996 | ‡2 BNE|XX1555590 | ||
| 996 | ‡2 BNC|981058517423806706 | ||
| 996 | ‡2 SUDOC|164545484 | ||
| 996 | ‡2 BNE|XX1009233 | ||
| 996 | ‡2 BNE|XX1008817 | ||
| 996 | ‡2 J9U|987007411833405171 | ||
| 996 | ‡2 BNE|XX1591600 | ||
| 996 | ‡2 NTA|071593632 | ||
| 996 | ‡2 NUKAT|n 2009086883 | ||
| 996 | ‡2 ISNI|0000000081062457 | ||
| 996 | ‡2 LC|n 90636780 | ||
| 996 | ‡2 RERO|A028116031 | ||
| 996 | ‡2 BNE|XX1700984 | ||
| 996 | ‡2 ISNI|0000000448828608 | ||
| 996 | ‡2 LC|nr2007005925 | ||
| 996 | ‡2 NII|DA02887764 | ||
| 996 | ‡2 ISNI|0000000060081608 | ||
| 996 | ‡2 BNE|XX1009088 | ||
| 996 | ‡2 LC|n 2009007224 | ||
| 996 | ‡2 DNB|105736715X | ||
| 996 | ‡2 J9U|987007379551105171 | ||
| 996 | ‡2 BNE|XX1236199 | ||
| 996 | ‡2 SUDOC|137129785 | ||
| 996 | ‡2 PTBNP|1588590 | ||
| 996 | ‡2 BLBNB|000311976 | ||
| 996 | ‡2 BNC|981058616043606706 | ||
| 996 | ‡2 N6I|vtls000078989 | ||
| 996 | ‡2 LC|n 78041448 | ||
| 996 | ‡2 BNE|XX1690021 | ||
| 996 | ‡2 ISNI|0000000066360501 | ||
| 996 | ‡2 ISNI|0000000023445628 | ||
| 996 | ‡2 ISNI|0000000079003095 | ||
| 996 | ‡2 NTA|191294187 | ||
| 996 | ‡2 NUKAT|n 2014135395 | ||
| 996 | ‡2 J9U|987007271536405171 | ||
| 996 | ‡2 BNE|XX924640 | ||
| 996 | ‡2 LC|n 2018040206 | ||
| 996 | ‡2 BNE|XX926113 | ||
| 996 | ‡2 PLWABN|9810583169905606 | ||
| 996 | ‡2 RERO|A000124663 | ||
| 996 | ‡2 LC|nb2013021192 | ||
| 996 | ‡2 N6I|vtls000031191 | ||
| 996 | ‡2 J9U|987007447942005171 | ||
| 996 | ‡2 NTA|134344626 | ||
| 996 | ‡2 SUDOC|228508886 | ||
| 996 | ‡2 BNE|XX5280260 | ||
| 996 | ‡2 LC|nb2021014924 | ||
| 996 | ‡2 BNC|981058529397506706 | ||
| 996 | ‡2 NII|DA07993995 | ||
| 996 | ‡2 LC|n 50034277 | ||
| 996 | ‡2 DNB|171533240 | ||
| 996 | ‡2 LC|no2014009792 | ||
| 996 | ‡2 LC|n 2010008664 | ||
| 996 | ‡2 NKC|vse2005299879 | ||
| 996 | ‡2 BAV|495_386314 | ||
| 996 | ‡2 RERO|A003654919 | ||
| 996 | ‡2 ISNI|0000000069616672 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
